Philips Wearable Biosensor
Friday, Royal Philips said that it has received Food and Drug Administration clearance for IntelliVue Guardian, a monitoring system that detects subtle signs of impending health issues for hospitalized patients. The 510(k) clearance allows the global company to pair IntelliVue Guardian with the single-use, adhesive Philips Wearable Sensor in the U.S.
The software acquired CE Mark certification for sale in Europe in October.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
“This little biosensor is the gap filler” that facilitates continuous monitoring of heart rate and respiration in high-acuity patients, said Dr. Kevin Dellsperger, CMO of Augusta (Georgia) University Health. Dellsperger was one of several participants in a Philips-sponsored breakfast discussion Monday at the annual Healthcare Information and Management Systems Society conference in Orlando, Florida.
In a pilot at Augusta University Medical Center, IntelliVue Guardian regularly was able to head off cardiac arrest and found an 88 percent reduction in “predictable” codes, Dellsperger reported.
“We found that 4-6 hours before someone arrested, there was a change in their vital signs,” Dellsperger, a cardiologist, said. “That change can be so subtle that residents miss it.” Sometimes, even attending physicians miss it, too.
This was but one of several pieces of news the Amsterdam-based technology company discussed Monday at HIMSS17.
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Philips unveiled IntelliSpace Enterprise Edition, which the vendor called the first hospital-wide informatics managed service. It essentially bundles various informatics functions into a pay-per-use package.
Another new flavor, IntelliSpace Genomics, delivers genomic data along with patient records, test results and medical images to the point of care. This will complement Illumeo, a next-generation sequencing platform the company debuted at the Radiological Society of North American scientific meeting in late November.
“This is sequencing at a massive scale,” Sanjay Chikarmane, general manager of enterprise informatics at DNA sequencing giant Illumina. Philips and Illumina last month entered into a strategic partnership to match sequencing and informatics technologies.
“We are bringing together our imaging devices with our analytics platform” to assist in the practice of precision medicine, Philips Connected Care & Health Informatics CEO Jeroen Tas said at the press conference.
In one consumer move on Monday, the health tech company unveiled a mobile app called Jovia Coach to help healthcare systems reach out to patients at risk for Type 2 diabetes. “If we track adherence [to population health programs], we might as well coach patients and we might as well connect them to their caregivers,” Tas said.
Photo: Philips